Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

03/24/2012 | 02:59am US/Eastern

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

Latest news on DAIICHI SANKYO COMPANY, LI
1d ago DAIICHI SANKYO : U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Make..
1d ago Cipher Reports Financial Results for Q3 2014
1d ago Ranbaxy sees first profit in six qtrs on Diovan sales
1d ago RANBAXY TURNS AROUND, POSTS Rs478-CRORE PROFIT IN Q2
2d ago DAIICHI SANKYO : Health and Human Services Department (HHS); Food and Drug Admin..
2d ago RANBAXY LABORATORIES : Q2 FY 2015 Sales Rs.32,180 Mn. H1 FY2015 Sales Rs.55,902 ..
2d ago DAIICHI SANKYO : Center for Connected Health and Daiichi Sankyo, Inc. Sign Agree..
2d ago Ranbaxy might lose nexium exclusivity
2d ago RANBAXY LABORATORIES : Q2 fy 2015 sales rs.32,180 mn. h1 fy2015 sales rs.55,902 ..
3d ago Ranbaxy surges after profit, Sun Pharma also gains
Advertisement
Chart
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF